STOCK TITAN

SAB Biotherapeutics: Vivo reports 22.3M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. (SABS) ownership disclosures list 22,287,501 shares, or 9.99% of the class, for Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, are reported at 2,251,010 shares, also 9.99%. These totals combine common stock with shares issuable upon conversion of Series B Preferred Stock and exercise of Enrollment and Data Release Warrants within 60 days. The totals assume full conversions and exercises without applying the blocking provisions: those securities cannot be converted or exercised if doing so would give the holder or its affiliates more than 9.99% of SABS voting securities.

Reported beneficial ownership — Vivo Opportunity Fund Holdings group 22,287,501 shares Reported as 9.99% of the class; includes shares issuable upon preferred-stock conversion and warrant exercise.
Reported beneficial ownership — Vivo Opportunity Cayman Fund group 2,251,010 shares Reported as 9.99% of the class; includes shares issuable upon preferred-stock conversion and warrant exercise.
Conversion and exercise blocker 9.99% Conversion or exercise is restricted if it would result in the holder or its affiliates exceeding this level of SABS voting securities.
beneficially own financial
"may be deemed to beneficially own an aggregate of"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Series B Preferred Stock financial
"shares issuable upon conversion of Series B Preferred Stock"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Enrollment Warrants financial
"shares of Series B Preferred Stock underlying Enrollment Warrants"
Data Release Warrants financial
"shares of Series B Preferred Stock underlying Data Release Warrants"
blocking provisions technical
"without giving effect to the blocking provisions"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SABS shares did Vivo report beneficially owning?

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, were reported at 22,287,501 shares (9.99%); Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, were reported at 2,251,010 shares (9.99%). The totals include common stock and shares issuable from preferred-stock conversions and warrants.

What is the SABS 9.99% limit on Vivo's preferred stock and warrants?

The Series B Preferred Stock, Enrollment Warrants, and Data Release Warrants cannot be converted or exercised if doing so would result in the holder or its affiliates obtaining more than 9.99% of SABS voting securities. The reported amounts count shares issuable upon full conversion and exercise without applying those blocking provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





78397T202

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 6,282,901 shares of common stock, par value $0.0001 per share (the "Common Stock") of SAB Biotherapeutics, Inc. (the "Issuer"), (ii) 446,000 shares of Common Stock issuable upon conversion of 4,460 shares of the Issuer's Series B Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock") convertible within 60 days of this Statement, (iii) 10,372,400 shares of Common Stock issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 5,186,200 shares of Common Stock issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 6,282,901 shares of Common Stock of the Issuer, (ii) 446,000 shares of Common Stock issuable upon conversion of 4,460 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 10,372,400 shares of Common Stock issuable upon conversion of 103,724 shares of Series B Preferred Stock underlying 103,724 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 5,186,200 shares of Common Stock issuable upon conversion of 51,862 shares of Series B Preferred Stock underlying 51,862 Data Release Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 632,110 shares of Common Stock of the Issuer, (ii) 47,500 shares of Common Stock issuable upon conversion of 475 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 1,047,600 shares of Common Stock issuable upon conversion of 10,476 shares of Series B Preferred Stock underlying 10,476 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 523,800 shares of Common Stock issuable upon conversion of 5,238 shares of Series B Preferred Stock underlying 5,238 Data Release Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 632,110 shares of Common Stock of the Issuer, (ii) 47,500 shares of Common Stock issuable upon conversion of 475 shares of the Issuer's Series B Preferred Stock, convertible within 60 days of this Statement, (iii) 1,047,600 shares of Common Stock issuable upon conversion of 10,476 shares of Series B Preferred Stock underlying 10,476 Enrollment Warrants that are exercisable within 60 days of this Statement, and (iv) 523,800 shares of Common Stock issuable upon conversion of 5,238 shares of Series B Preferred Stock underlying 5,238 Data Release Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrant all contain provisions preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the Enrollment Warrants and the Data Release Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the blocking provisions.


SCHEDULE 13G



Vivo Opportunity Fund Holdings, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:11/16/2026
Vivo Opportunity, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/16/2026
Vivo Opportunity Cayman Fund, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
Date:11/16/2026
Vivo Opportunity Cayman, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/16/2026

Keep reading